Scientific Publications

Abstract: Background: Adequate intragastric pH elevation is critical for antibiotic efficacy in H. pylori eradication regimens. The relationship between PPI pharmacokinetics and the achievement of sustained pH targets has important implications for optimizing treatment protocols. Methods: We conducted pharmacokinetic/pharmacodynamic modeling of esomeprazole and omeprazole across CYP2C19 metabolizer genotypes and evaluated the downstream effects on clarithromycin and amoxicillin stability at varying pH levels. Results: Esomeprazole demonstrated superior and more consistent intragastric pH control compared to omeprazole across all CYP2C19 genotypes, particularly in extensive metabolizers who represent the majority of the population. Antibiotic stability at pH ≥6 was significantly greater than at pH ≤4 for both clarithromycin and amoxicillin. Conclusions: These findings support the pharmacokinetic rationale for PPI selection in H. pylori eradication regimens and suggest that achieving consistent pH ≥6 for ≥18 hours per day may optimize eradication outcomes, particularly in patients with high CYP2C19 activity.

Abstract: The cytotoxin-associated gene A (CagA) protein of Helicobacter pylori is translocated into gastric epithelial cells via the Type IV secretion system, where it undergoes tyrosine phosphorylation and interacts with multiple host signaling proteins including SHP-2 phosphatase and Grb2 adaptor protein. This review synthesizes current understanding of CagA-induced signaling alterations, including activation of Ras-ERK and PI3K-Akt pathways, suppression of tumor suppressor functions, and disruption of tight junction integrity. We discuss the implications of these interactions for gastric carcinogenesis and identify potential therapeutic opportunities for interrupting CagA-host protein interactions as an adjunct to antibiotic eradication. The development of small molecules targeting the CagA-SHP-2 interaction represents a potentially productive direction for drug discovery in H. pylori-associated gastric disease.

Abstract: Clarithromycin resistance in H. pylori, mediated primarily by point mutations in the 23S rRNA gene (A2142G, A2143G), has emerged as a major obstacle to successful eradication with standard triple therapy. This study examined clarithromycin resistance rates in clinical H. pylori isolates from multiple geographic regions and evaluated the performance of standard triple therapy versus bismuth quadruple therapy as a function of local resistance prevalence. H. pylori isolates from 847 patients were cultured and tested for clarithromycin susceptibility by E-test and PCR-based resistance mutation analysis. Our results demonstrate a significant inverse correlation between local clarithromycin resistance rates and triple therapy eradication success, supporting the adoption of resistance-guided therapy selection and the use of bismuth quadruple therapy as first-line treatment in regions with clarithromycin resistance exceeding 15%. These findings have important implications for the design of empirical treatment guidelines.

Abstract: Helicobacter pylori vacuolating cytotoxin A (VacA) is a secreted toxin that forms anion-selective channels in cell membranes, inducing vacuolation, disrupting mitochondrial function, and promoting apoptosis in gastric epithelial cells. This review examines VacA structure-function relationships, receptor binding mechanisms involving sphingomyelin and receptor protein tyrosine phosphatase β, and the downstream cellular consequences of VacA intoxication. We present data from in vitro and in vivo models demonstrating VacA's contributions to mucosal barrier disruption, enhanced bacterial colonization, and immune cell modulation that collectively facilitate H. pylori persistence. Discussion addresses the potential for VacA as a vaccine antigen and the therapeutic relevance of blocking VacA-mediated cellular injury as a complementary strategy to antibiotic eradication.